Vertex, Beam Report SCD Cell and Gene Therapies Advances at ASH 2024

Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026.

Scroll to Top